[논문]Novel HBV mutations and their value in predicting efficacy of conventional interferon

Wu, D.X.; Fu, X.Y.; Gong, G.Z.; Sun, K.W.; Gong, H.Y.; Wang, L.; Wu, J.; Tan, D.M.

doi:10.1016/S1499-3872(16)60184-4

[해외논문] Novel HBV mutations and their value in predicting efficacy of conventional interferon

Hepatobiliary & pancreatic diseases international : HBPD INT, v.16 no.2, 2017년, pp.189 - 196

Wu, D.X. , Fu, X.Y. , Gong, G.Z. , Sun, K.W. , Gong, H.Y. , Wang, L. , Wu, J. , Tan, D.M.

Abstract ▼ AI-Helper

Background: Accumulating studies assessing the impacts of hot spot mutations on conventional interferon (IFN) efficacy come to discrepant conclusions; studies regarding the mutations in S and RT regions are also unclear. The present study aimed to evaluate the impacts of HBV mutations on the efficacy of conventional IFN. Methods: A total of 126 patients who received conventional IFN treatment for 48 weeks were enrolled. Biochemical and serological parameters were routinely tested. The sequences of HBV from 78 serum samples were amplified by nested-PCR; mutations were identified with sequence scanner V1.0 after ABI 3730xl direct sequencing, HBV genotypes were determined according to RT gene sequences utilizing NCBI Genotyping Tool which was based on phylogenetic analysis. Results: The baseline DNA levels of virological response (VR) group were significantly lower than those of no VR group [7.13+/-0.76 vs 7.69+/-0.56 lg (copies/mL), P =0.001]. The baseline ALT levels were significantly higher in the HBeAg clearance group (204.72+/-88.65 vs 162.80+/-85.81 IU/L, P<0.05) and HBeAg seroconversion group (204.89+/-95.68 vs 166.75+/-84.43 IU/L, P<0.05). Females and lower BMI levels (20.01+/-2.33 vs 21.65+/-3.66 kg/m2, P<0.05) were prone to acquired biochemical response (BR). PC-W28STOP (ntG1896A) was significantly higher in the combined response (CR) group than that in the no CR group (91.7% vs 39.7%, P=0.001). Multivariate logistic regression analysis showed that baseline DNA, PC-P159T (ntC2288A), BCP-N118T (ntA1726C) and BCP-L134L (ntA1775C/G/T) influenced VR independently. PC-G182C (ntG2357T), PC-S64A/T (ntT2003G/A) and BMI were independent influence factors for HBeAg clearance, HBeAg seroconversion and BR, respectively. The new predicting model concluded that baseline DNA and new mutations for VR were established successfully, and ROC analysis showed that AUC was 0.842 (P<0.001) with a sensitivity of 0.652 and a specificity of 0.933. Conclusions: PC-P159T (ntC2288A), BCP-N118T (ntA1726C), BCP-L134L (ntA1775C/G/T), PC-G182C (ntG2357T) and PC-S64A/T (ntT2003G/A) were novel identified mutations that impacted IFN therapeutic efficacy. These novel mutations could serve as important predictors before conventional IFN treatment.

Keyword

참고문헌 (32)

J Hepatol European Association For The Study Of The Liver 57 167 2012 10.1016/j.jhep.2012.02.010 EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

상세보기
Chin Med J (Engl) Lu 122 3 2009 Management of hepatitis B in China
J Hepatol Fattovich 48 335 2008 10.1016/j.jhep.2007.11.011 Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors

상세보기
Clin Liver Dis Roche 17 451 2013 10.1016/j.cld.2013.05.003 Treatment of patients with HBV-related decompensated cirrhosis and liver transplanted patients

상세보기
National Clinical Guideline Centre (UK) 2013 National Institute for Health and Care Excellence: Clinical Guidelines
Hepatology Lok 45 507 2007 10.1002/hep.21513 Chronic hepatitis B

상세보기
Gastroenterology Zoulim 137 1593 2009 10.1053/j.gastro.2009.08.063 Hepatitis B virus resistance to nucleos(t)ide analogues

상세보기
BMJ Sarri 346 f3893 2013 10.1136/bmj.f3893 Diagnosis and management of chronic hepatitis B in children, young people, and adults: summary of NICE guidance

상세보기
Expert Opin Pharmacother Chen 17 355 2016 10.1517/14656566.2016.1118056 Pharmacotherapeutic options for hepatitis B

상세보기
Antiviral Res Gish 121 47 2015 10.1016/j.antiviral.2015.06.008 Chronic hepatitis B: Virology, natural history, current management and a glimpse at future opportunities

상세보기
Antiviral Res Sonneveld 97 312 2013 10.1016/j.antiviral.2012.12.023 Hepatitis B e antigen levels and response to peginterferon: influence of precore and basal core promoter mutants

상세보기
Hepatology Sonneveld 56 67 2012 10.1002/hep.25636 Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B

상세보기
Zhonghua Gan Zang Bing Za Zhi Chinese Society of Hepatology and Chinese Society of Infectious Diseases 19 13 2011 The guideline of prevention and treatment for chronic hepatitis B (2010 version)

상세보기
Indian J Med Microbiol Hamidi-Fard 31 360 2013 10.4103/0255-0857.118882 Mutation analysis of hepatitis B virus reverse transcriptase region among untreated chronically infected patients in Ahvaz city (South-West of Iran)

상세보기
J Virol Methods Han 193 341 2013 10.1016/j.jviromet.2013.06.015 Analysis of hepatitis B virus genotyping and drug resistance gene mutations based on massively parallel sequencing

상세보기
Carcinogenesis Gouas 33 1219 2012 10.1093/carcin/bgs135 TP53 R249S mutation, genetic variations in HBX and risk of hepatocellular carcinoma in The Gambia

상세보기
J Gastroenterol Xu 46 391 2011 10.1007/s00535-010-0315-4 Association of hepatitis B virus mutations in basal core promoter and precore regions with severity of liver disease: an investigation of 793 Chinese patients with mild and severe chronic hepatitis B and acute-on-chronic liver failure

상세보기
Hepatol Int Liaw 6 531 2012 10.1007/s12072-012-9365-4 Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update

상세보기
Curr Opin Infect Dis Krishnamoorthy 28 557 2015 10.1097/QCO.0000000000000209 Hepatitis B: encouraging the use of interferon

상세보기
Clin Gastroenterol Hepatol Konerman 13 386 2015 10.1016/j.cgh.2014.08.024 Is it more cost-effective for patients with chronic hepatitis b to have a trial of interferon before considering Nucleos(t)ide analogue therapy?

상세보기
N Engl J Med Niederau 334 1422 1996 10.1056/NEJM199605303342202 Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B

상세보기
Hepatology van Zonneveld 39 804 2004 10.1002/hep.20128 Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B

상세보기
Gastroenterology Lok 120 1828 2001 10.1053/gast.2001.24839 Management of hepatitis B: 2000-summary of a workshop

상세보기
Clin Gastroenterol Hepatol Keeffe 6 1315 2008 10.1016/j.cgh.2008.08.021 A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update

상세보기
Int J Clin Exp Pathol Li 6 1076 2013 Accumulation of the mutations in basal core promoter of hepatitis B virus subgenotype C1 increase the risk of hepatocellular carcinoma in Southern China
Antiviral Res Hung 93 55 2012 10.1016/j.antiviral.2011.10.018 Precore/core promoter mutations and hepatitis B virus genotype in hepatitis B and C dually infected patients treated with interferon-based therapy

상세보기
Middle East J Dig Dis Mohamadkhani 3 13 2011 The importance of hepatitis B virus genome diversity in Basal core promoter region
Hepatology Yang 57 934 2013 10.1002/hep.26121 Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion

상세보기
Open Virol J Hakami 7 12 2013 10.2174/1874357901307010012 Effects of hepatitis B virus mutations on its replication and liver disease severity

상세보기
J Med Virol Li 85 1698 2013 10.1002/jmv.23640 A complete genomic analysis of hepatitis B virus isolated from 516 Chinese patients with different clinical manifestations

상세보기
Hepatogastroenterology Xu 59 212 2012 Pre-core/basal-core promoter and reverse transcriptase mutations in chronic HBV infected-patients

상세보기
J Virol Zheng 78 6908 2004 10.1128/JVI.78.13.6908-6914.2004 Regulation of hepatitis B virus core promoter by transcription factors HNF1 and HNF4 and the viral X protein

상세보기

활용도 분석정보

상세보기

다운로드

내보내기

활용도 Top5 논문

해당 논문의 주제분야에서 활용도가 높은 상위 5개 콘텐츠를 보여줍니다.
더보기 버튼을 클릭하시면 더 많은 관련자료를 살펴볼 수 있습니다.

내보내기 구분	파일저장 인쇄 메일전송
구성항목	기본정보 상세정보 관리번호, 논문명, 저널/프로시딩명, 저자 , 발행년, 권, 호, 시작페이지, 끝페이지, 발행기관 관리번호, 논문명, 대등논문명, 저자 , 저널/프로시딩명, 발행기관, 발행년, 발행언어, 권, 호, 시작페이지, 끝페이지, ISBN, ISSN, 주제분야, 키워드, 초록(한글), 초록(영문), 저자(소속기관)
저장형식	Text(ASCII format) Excel format RefWorks Direct Export RIS format (for Reference Manager, ProCite, EndNote), Scholar's Aids, Mendeley
메일정보	받는사람 (필수) @ 보내는사람 (선택) @ 제목 내용 KISTI 검색결과 이메일 서비스
안내	총 건의 자료가 검색되었습니다. 다운받으실 자료의 인덱스를 입력하세요. (1-10,000) 검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다. 데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요) 다운로드 파일은 UTF-8 형태로 저장됩니다. 파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오. ~ Text(ASCII format) Excel format

연합인증